Xenon Pharmaceuticals Inc.
XENE
Jodie situation report
Xenon Pharmaceuticals Inc.'s current read is isolated; its market group is not confirming.
The latest filing evidence is available. 0 of 2 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 3 directly disclosed connections are confirming.
- The operating loss widened by 28.9M.
- Xenon reports higher R&D spending tied to azetukalner Phase 3 studies and manufacturing for a planned NDA submission, with no revenue in the latest three months.
- Direct external costs for azetukalner increased by $15.6M in the quarter, attributed to ongoing Phase 3 clinical studies in MDD and BPD.
Invalidation: The isolated read changes if XENE's group or a disclosed connection begins moving with it.
Who this business touches
The relationships behind XENE
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
NBIXNeurocrine Biosciences, Inc.partnerMay 7, 2026 ▾
“Our Partnered Program with Neurocrine Biosciences In December 2019, we entered into a license and collaboration agreement with Neurocrine Biosciences to develop treatments for epilepsy.”
JAZZJazz Pharmaceuticals plccompetitorFeb 26, 2026 ▾
“There are other ASMs in development that could potentially compete with our products, including product candidates in development from Biohaven Ltd., Jazz Pharmaceuticals, plc, Neurona Therapeutics Inc., NeuShen Therapeutics, Inc., Otsuka Pharmaceutical Co.”
Depended on by
NBIXNeurocrine Biosciences, Inc.partnerFeb 11, 2026 ▾
“Some of our other collaborators include Nxera Pharma UK Limited (formerly Sosei Heptares), Takeda Pharmaceutical Company Limited, Voyager Therapeutics, Inc., and Xenon Pharmaceuticals Inc.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
XENE is currently a Leader in the organic co-movement group Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.